These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 25935098

  • 1. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
    Peace JH, Ahlberg P, Wagner M, Lim JM, Wirta D, Branch JD.
    Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S, Paredes T, Goldberg I, Coote M, Wells A, Volksone L, Pillai MR, Stalmans I, Denis P, Travoprost Bak-Free Clinical Study Group.
    Eur J Ophthalmol; 2012 Aug; 22(1):34-44. PubMed ID: 22167541
    [Abstract] [Full Text] [Related]

  • 3. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
    Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV, Travoprost BAC-free Study Group.
    J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
    [Abstract] [Full Text] [Related]

  • 4. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI.
    J Glaucoma; 2008 Jan; 17(3):217-22. PubMed ID: 18414108
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K.
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [Abstract] [Full Text] [Related]

  • 6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 7. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF, Hubatsch DA, Amaris P.
    BMC Ophthalmol; 2015 Nov 12; 15():166. PubMed ID: 26563363
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT, Sullivan EK, Landry TA, Bergamini MV, Robertson SM.
    Am J Ophthalmol; 2005 Aug 12; 140(2):242-50. PubMed ID: 16086946
    [Abstract] [Full Text] [Related]

  • 9. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D.
    Eur J Ophthalmol; 2007 Aug 12; 17(2):183-90. PubMed ID: 17415690
    [Abstract] [Full Text] [Related]

  • 10. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
    Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y.
    Eye (Lond); 2011 Sep 12; 25(9):1161-9. PubMed ID: 21701528
    [Abstract] [Full Text] [Related]

  • 11. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA, Bergamini MV.
    J Glaucoma; 2005 Oct 12; 14(5):392-9. PubMed ID: 16148589
    [Abstract] [Full Text] [Related]

  • 12. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB, Hubatsch DA.
    BMC Ophthalmol; 2014 Nov 28; 14():151. PubMed ID: 25432143
    [Abstract] [Full Text] [Related]

  • 13. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, Bergamini MV.
    Am J Ophthalmol; 2005 Jul 28; 140(1):1-7. PubMed ID: 15990081
    [Abstract] [Full Text] [Related]

  • 14. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S.
    Surv Ophthalmol; 2004 Mar 28; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [Abstract] [Full Text] [Related]

  • 15. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R.
    Clin Ther; 2007 Sep 28; 29(9):1915-23. PubMed ID: 18035191
    [Abstract] [Full Text] [Related]

  • 16. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
    Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK, International Travoprost Study Group.
    J Glaucoma; 2001 Oct 28; 10(5):414-22. PubMed ID: 11711841
    [Abstract] [Full Text] [Related]

  • 17. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M, Oshima H, Araie M, EXTraKT study group.
    Acta Ophthalmol; 2013 Feb 28; 91(1):e7-e14. PubMed ID: 23241328
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM, Tanna AP, Gross RL, Chuang AZ, Baker L, Reynolds A, Prager TC, Additivity Study Group.
    Ophthalmology; 2007 Jul 28; 114(7):1248-54. PubMed ID: 17509688
    [Abstract] [Full Text] [Related]

  • 19. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M, Ikeda Y, Mizoue S, Arakaki Y, Kita N, Kobayashi S, NEXTraKT Study Group.
    J Glaucoma; 2016 Jun 28; 25(6):e610-4. PubMed ID: 25967526
    [Abstract] [Full Text] [Related]

  • 20. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N, Sahin A, Gultekin S.
    J Glaucoma; 2008 Jun 28; 17(1):36-9. PubMed ID: 18303382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.